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Introduction 
Sweet syndrome is a condition characterized by such 
major criteria as the sudden onset of tender 
erythematous papulonodules with histopathologic 
evidence of a diffuse predominantly neutrophilic 
infiltrate [1]. Additional minor criteria for this 
diagnosis include: the presence of fever in 40-80% of 
patients, elevated erythrocyte sedimentation rate, C-
reactive protein, leukocytosis, and neutrophilia, 
excellent response to systemic corticosteroids, and 
an association with chronic inflammatory disorders 
such as infection, malignancy, drug exposure, 
pregnancy, or myeloproliferative disorders [2, 3]. 
While systemic manifestations such as arthralgia, 
myalgia, and ocular involvement are common, 
pulmonary findings are a rare manifestation with 
only 45 total reported cases and one case published 
in the dermatologic literature, to our knowledge [4, 
Abstract 
We report a patient with Sweet syndrome involving 
the pulmonary system in the context of 
myelodysplastic syndrome. Although Sweet 
syndrome may involve a variety of organ systems, the 
pulmonary system is rarely affected and can result in 
poor clinical outcomes, including acute respiratory 
distress syndrome. Both cutaneous and pulmonary 
symptoms respond well to systemic corticosteroid 
therapy and early diagnosis and treatment can 
improve the prognosis. Our case highlights the 
importance of collaboration between hematologists, 
dermatologists, and pulmonologists to facilitate 
effective diagnosis, triage, and treatment of these 
patients. 
 
Figure 1: Clinical photographs of bilateral upper and lower 
extremities with violaceous papules and nodules. A) Upper 
extremities and B) lower extremities at initial clinical presentation 
and C) upper extremity improvement and D) lower extremity 
improvement after 8 weeks of oral prednisone.  
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5]. In this case report, we demonstrate a rare case of 
Sweet syndrome with radiologic evidence of 
pulmonary involvement that rapidly improved with 
corticosteroids. 
 
Case Synopsis 
A 59-year-old woman with a past medical history of 
asthma, gallbladder pancreatitis, and a 30 pack-year 
smoking history was admitted with fevers of 38.7C, 
poor appetite, fatigue, nausea, and 5.9kg weight loss 
in the setting of pancytopenia. The patient also had 
one week of tender violaceous papules on both  
upper and lower extremities (Figure 1A, B). 
Laboratory tests were significant for a white blood 
count of 4.4×109/L, hemoglobin of 6.0g/dL, 
hematocrit of 16.8%, platelet of 30×109/L, C-reactive 
protein of 38.39mg/L, erythrocyte sedimentation 
rate of 140mm/h, and negative anti-neutrophilic 
cytoplasmic antibody. Urinalysis and comprehensive 
metabolic panel were within normal limits. Initial 
chest computed tomography scan without contrast 
(Figure 2) demonstrated extensive ground glass 
opacities more prominent in the lower lobes, 
believed to be suggestive of an opportunistic 
infection. The patient was placed empirically on 
intravenous cefepime, azithromycin, metronidazole, 
and acyclovir. A bone marrow biopsy was obtained 
one day after admission and demonstrated 
hypercellular marrow with 11.6% lymphoblasts 
consisting of dysplastic myeloid precursors. 
Cytogenetics tests were positive for amplification of 
the lysine methyltransferase 2A gene (KMT2A) 
detected on fluorescent in situ hybridization (FISH), 
concerning for myelodysplastic syndrome (MDS) 
with a poor prognosis. Bronchosocopy was 
performed given persistent fevers and radiographic 
evidence of ground glass opacities and 
bronchoalveolar lavage cultures were negative for 
legionella, acid-fast bacteria, and fungus. Smears  
 
Figure 3: H&E stain of biopsy of violaceous nodule on left anterior shin. A) Low power (2×), and B) higher magnification (20×) sections 
revealed focal parakeratosis and mild spongiosis overlying a deep dermal and subcutaneous neutrophil-rich inflammatory infiltrate 
with an adjacent reactive fibroblastic reaction and hemorrhage. Gram, Grocott methenamine silver, and periodic acid-Schiff stains were 
negative. 
 
Figure 2: High resolution chest CT scan. The helical CT imaging of 
the chest shows bilateral extensive ground glass and nodular 
opacities on a background of interstitial thickening and 
emphysema both in A) coronal and B) sagittal planes. 
A C B 
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demonstrated alveolar macrophages with 
neutrophils. Despite intravenous antibiotics, the 
patient had persistent fevers with negative blood 
and urine cultures. Decitabine therapy was started 
11 days after admission to address persistent fevers 
thought to be secondary to MDS. 
A dermatology consultation was subsequently 
obtained 24 days after admission for persistent 
violaceous nodules on the lower extremities. A 
biopsy of a lesion on the left anterior shin showed 
focal parakeratosis and mild spongiosis overlying a 
deep dermal, subcutaneous, and peri-eccrine 
neutrophil rich inflammatory infiltrate (Figure 3). 
Tissue culture was negative for aerobic and 
anaerobic bacteria, acid-fast bacteria, atypical 
mycobacteria, nocardia, and fungus. One day 
following consultation, the patient developed acute 
hypoxic respiratory distress and was transferred to 
the ICU. Repeat chest CT showed interval worsening 
of bilateral ground glass opacities and nodular 
opacities throughout both lungs. The patient was 
treated with vancomycin and piperacillin-
tazobactam for possible pneumonia along with 
intravenous methylprednisolone. 
The neutrophil-rich infiltrates on biopsy along with 
radiologic pulmonary findings was concerning for a 
diagnosis of Sweet syndrome with pulmonary 
involvement. Consequently, the antibiotics were 
stopped and the patient continued intravenous 
methylprednisolone followed by a 6-week oral 
prednisone taper. The patient experienced rapid 
improvement in her pulmonary symptoms and her 
fevers resolved. Follow-up two months after 
discharge demonstrated complete resolution of 
ground glass opacities and pleural effusions on CT 
along with marked improvement in cutaneous 
symptoms (Figure 1C, D). 
 
Case Discussion 
In this case, we present a patient with clinical, 
histopathologic, radiologic, and bronchoalveolar 
lavage evidence of Sweet syndrome with pulmonary 
involvement in the context of negative cultures and 
MDS. The patient’s constitutional and respiratory 
symptoms did not improve with empiric antibiotics,  
suggesting lack of infection. The differential 
diagnosis also included Sweet syndrome, pyoderma 
gangrenosum, neutrophilic eccrine hidradenitis, 
ulcerating neutrophilic panniculitis related to alpha-
1-antitrypsin deficiency syndrome, and vasculitis. 
However, the rash preceded decitabine 
administration and the lack of ulcerating lesions or 
elevated liver function tests did not support 
pyoderma gangrenosum or alpha-1-antitrypsin 
deficiency syndrome, respectively. Pathology, 
negative ANCA, and normal urinalysis were also less 
suggestive of vasculitis. Furthermore, our patient 
fulfilled two major criteria for Sweet syndrome: the 
presence of erythematous violaceous 
papulonodules and dense neutrophilic infiltrate on 
biopsy. Additionally, she fulfilled four minor criteria, 
including: general malaise and fevers >38C, a 
concomitant diagnosis of MDS, elevated C-reactive 
protein, erythrocyte sedimentation rate, and 
neutrophilia on bronchoalveolar lavage, and a rapid 
response to systemic corticosteroids [6]. The ground 
glass opacities, interstitial infiltrates on chest CT, 
neutrophilia on bronchoalveolar lavage, and acute 
hypoxic respiratory distress with prompt response to 
corticosteroids indicated pulmonary involvement as 
well. 
Symptoms of pulmonary Sweet typically involve 
progressive dyspnea and a dry nonproductive cough 
that typically present concomitantly with cutaneous 
lesions [7]. Chest X-ray and chest CT show diffuse 
unilateral or bilateral interstitial infiltrates, with some 
cases demonstrating pulmonary ground glass 
opacities and pleural effusions. Bronchoalveolar 
lavage often reveals a high neutrophil content 
(>50%) with negative cultures, whereas 
transbronchial biopsies show dense, sterile 
neutrophilic alveolar infiltrates. In 16 of 34 cases of 
Sweet syndrome with pulmonary involvement the 
skin manifestations presented first, whereas in 12 
cases the two occurred simultaneously [7, 8]. In this 
case, our patient was found to have violaceous 
papulonodules prior to having a screening chest CT, 
which demonstrated bilateral lower lobe infiltrates 
and ground glass opacities. Although our patient 
recovered lung function with significant 
improvement of cutaneous lesions on systemic  
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corticosteroids, Sweet syndrome with pulmonary 
involvement has, in five cases, rapidly progressed to 
acute respiratory distress syndrome and death [7]. 
Furthermore, as seen in our patient, of 34 previous 
reported cases of pulmonary involvement in Sweet 
syndrome, 18 cases involved the presence of 
hematologic disorders, including MDS, 
myeloproliferative disorder, and agnogenic myeloid 
metaplasia [9, 10]. 
 
Conclusion 
We report a patient with Sweet syndrome with 
pulmonary involvement in the setting of MDS. We 
hope that this case will add to the literature 
regarding systemic manifestations of Sweet 
syndrome. This case serves as an important reminder 
of the rare systemic manifestations of Sweet 
syndrome while also demonstrating the importance 
of interdisciplinary collaboration between 
dermatologists, pulmonologists, and hematologists 
to optimize the management and outcomes of 
patients suffering from Sweet syndrome. 
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